Hormonal
There is a negative correlation between glycemic control (HbA1c reduction) and body weight reduction at the between-study level in all participants, but a positive correlation exists when analyzing patients with diabetes or non-diabetic participants separately.
For people with diabetes, GLP-1 RAs tend to improve both blood sugar and weight loss together. For non-diabetic individuals, these drugs still cause weight loss, but this may not translate to improved blood sugar markers since their levels are already normal. The relationship between weight loss and glycemic control is complex and depends on your starting health status.
The standardized pooled correlation coefficient between HbA1c levels and body weight was -0.42. A negative correlation between glycemic control and weight reduction was obtained.
Why this rating
Multivariate meta-analysis using structural equation modeling on 31 RCTs.
Source
Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis
Tzu‐Lin Yeh et al. · PLoS ONE · 2023
DOI 10.1371/journal.pone.0278685
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →